Related Experiment Video

Updated: Apr 23, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

20.8K

[Pharmaceutical treatment of advanced urinary bladder cancer: new developments in 2014]

S C Schmid1, J E Gschwend, M Retz

  • 1Arbeitsgemeinschaft Urologische Onkologie der Deutschen Krebsgesellschaft (AUO), Urologische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Straße 22, 81675, München, Deutschland, sebastian.schmid@lrz.tum.de.

Der Urologe. Ausg. A
|September 20, 2014
PubMed

Insights

Perioperative treatment for muscle-invasive bladder cancer is standard. Programmed cell death protein 1 (PD1) and PD1-ligand 1 (PD1-L1) inhibitors offer new immunomodulation therapies for advanced bladder cancer.

Area of Science:

  • Oncology
  • Immunotherapy
  • Urothelial Carcinoma

Context:

  • Muscle-invasive bladder cancer (MIBC) treatment paradigms are evolving.
  • Emerging immunomodulatory agents are transforming advanced bladder cancer care.
  • Standardization of perioperative treatment for MIBC is a recent development.

Purpose:

  • To review current and emerging data on pharmaceutical treatments for advanced bladder cancer.
  • To highlight the impact of programmed cell death protein 1 (PD1) and PD1-ligand 1 (PD1-L1) inhibitors.
  • To assess potential changes in the treatment landscape of advanced bladder cancer.

Summary:

  • Reviews literature from Medline PubMed and major urology/oncology conferences (EAU, ASCO, ASCO GU, AUA).
  • Focuses on data influencing or potentially influencing pharmaceutical treatment of advanced bladder cancer.
  • Discusses the role of PD1 and PD1-L1 inhibitors in immunomodulation therapy for metastatic bladder cancer.

Impact:

  • Provides insights into the evolving standard of care for advanced bladder cancer.
  • Informs clinicians about the potential of novel immunotherapies in bladder cancer treatment.
  • Contributes to understanding the shifting landscape of pharmaceutical interventions in urothelial carcinoma.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.2K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

14.4K

Related Concept Videos

Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
1.0K
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
414
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Urinary Tract Infection IV: Nursing Management01:17

Urinary Tract Infection IV: Nursing Management

In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
666
Urinary Tract Calculi V: Nursing Management01:28

Urinary Tract Calculi V: Nursing Management

AssessmentSubjective Data: Obtain a detailed health history, including any recent or chronic urinary tract infections, periods of immobilization, previous episodes of renal calculi, and medical conditions such as gout, benign prostatic hyperplasia, or hyperparathyroidism. Review the medication history for drugs that may influence stone formation, including allopurinol, analgesics, loop diuretics, or thiazide diuretics. Document the use of long-term indwelling catheters and any past surgical...
491